Current and historical daily PE Ratio for Shanghai Fosun Pharmaceutical (Group) Co Ltd (
) from 2014 to Jun 13 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Shanghai Fosun Pharmaceutical (Group) stock (SFOSF) PE ratio as of Jun 13 2024 is 31.64.
More Details
Shanghai Fosun Pharmaceutical (Group) Co Ltd (SFOSF) PE Ratio (TTM) Chart
Shanghai Fosun Pharmaceutical (Group) Co Ltd (SFOSF) PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Total 1249
- 1
- 2
- 3
- 4
- 5
- 6
- 14
Shanghai Fosun Pharmaceutical (Group) PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-14 | 15.2 | 2024-04-11 | 14.9 |
2024-06-13 | 15.2 | 2024-04-10 | 14.9 |
2024-06-12 | 15.2 | 2024-04-09 | 14.7 |
2024-06-11 | 15.2 | 2024-04-08 | 14.7 |
2024-06-10 | 15.2 | 2024-04-05 | 14.7 |
2024-06-07 | 15.2 | 2024-04-04 | 15.3 |
2024-06-06 | 15.2 | 2024-04-03 | 15.3 |
2024-06-05 | 15.2 | 2024-04-02 | 15.5 |
2024-06-04 | 15.2 | 2024-04-01 | 16.3 |
2024-06-03 | 15.2 | 2024-03-28 | 16.2 |
2024-05-31 | 16.5 | 2024-03-27 | 13.4 |
2024-05-30 | 16.5 | 2024-03-26 | 13.7 |
2024-05-29 | 16.5 | 2024-03-25 | 13.3 |
2024-05-28 | 16.5 | 2024-03-22 | 14.2 |
2024-05-24 | 16.5 | 2024-03-21 | 14.0 |
2024-05-23 | 16.5 | 2024-03-20 | 14.0 |
2024-05-22 | 16.5 | 2024-03-19 | 14.8 |
2024-05-21 | 16.5 | 2024-03-18 | 15.1 |
2024-05-20 | 16.5 | 2024-03-15 | 15.1 |
2024-05-17 | 16.5 | 2024-03-14 | 15.2 |
2024-05-16 | 15.4 | 2024-03-13 | 15.2 |
2024-05-15 | 15.4 | 2024-03-12 | 15.2 |
2024-05-14 | 15.4 | 2024-03-11 | 15.2 |
2024-05-13 | 15.4 | 2024-03-08 | 14.6 |
2024-05-10 | 15.4 | 2024-03-07 | 14.7 |
2024-05-09 | 15.4 | 2024-03-06 | 15.0 |
2024-05-08 | 15.4 | 2024-03-05 | 14.7 |
2024-05-07 | 15.4 | 2024-03-04 | 14.5 |
2024-05-06 | 15.4 | 2024-03-01 | 14.8 |
2024-05-03 | 15.1 | 2024-02-29 | 14.2 |
2024-05-02 | 15.1 | 2024-02-28 | 14.0 |
2024-05-01 | 15.1 | 2024-02-27 | 14.4 |
2024-04-30 | 15.1 | 2024-02-26 | 15.2 |
2024-04-29 | 15.1 | 2024-02-23 | 14.4 |
2024-04-26 | 14.9 | 2024-02-22 | 14.4 |
2024-04-25 | 14.9 | 2024-02-21 | 14.2 |
2024-04-24 | 14.9 | 2024-02-20 | 14.0 |
2024-04-23 | 14.9 | 2024-02-16 | 13.9 |
2024-04-22 | 14.9 | 2024-02-15 | 12.9 |
2024-04-19 | 14.9 | 2024-02-14 | 12.7 |
2024-04-18 | 14.9 | 2024-02-13 | 14.3 |
2024-04-17 | 14.9 | 2024-02-12 | 14.2 |
2024-04-16 | 14.9 | 2024-02-09 | 14.2 |
2024-04-15 | 14.9 | 2024-02-08 | 14.5 |
2024-04-12 | 14.9 | 2024-02-07 | 13.8 |
Shanghai Fosun Pharmaceutical (Group) Co Ltd (SFOSF) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Shanghai Fosun Pharmaceutical (Group) Co Ltd Shanghai Fosun Pharmaceutical (Group) Co Ltd logo](https://static.gurufocus.com/logos/0C00000OSZ.png?14)
Shanghai Fosun Pharmaceutical (Group) Co Ltd
NAICS : 325412
ISIN : CNE100001M79
Share Class Description:
SFOSF: Class HCompare
Compare
Traded in other countries / regions
600196.China02196.Hong KongSFOSF.USA08HH.Germany IPO Date
2014-04-15Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.